Amgen's First Research and Development Day Highlighted 24 of the Approximately 40 Programs in its Pipeline
Company Reported 14 Programs in Phase 2 or Phase 3 Clinical Development
Company Discussed 7 New Research and Development Programs in Inflammation,
Oncology or Pain Management and New Clinical Study Data from 3 Molecules
NEW YORK, March 23 -- Amgen Inc. (Nasdaq: AMGN),
the world's largest biotechnology company, today held its first-ever Research
and Development (R&D) review meeting. The company highlighted 24 programs
that are currently in human clinical studies or are expected to enter human
clinical studies in 2004. Overall, the company has approximately 40 programs
in development, including 14 in Phase 2 or Phase 3. Seven programs in
oncology, inflammation or pain management were discussed for the first time
today along with new clinical data from three drug candidates.
"Our efforts over the last few years have resulted in significant
increases in R&D productivity," said Kevin Sharer, Amgen's chairman and chief
executive officer. "We continue to attract some of the industry's best and
brightest scientists, encouraged by Amgen's R&D scope, capability, leadership
and the commercial potential of our pipeline."
R&D at Amgen
Amgen's global R&D organization is focused on five therapeutic areas:
inflammation, oncology, metabolic disease and osteoporosis, hematology and
nephrology, and neurology.
As evidence of its increased R&D productivity, the company reported that
more product candidates have entered into development at Amgen during the past
three years than in the previous 10 years combined. In 2003, the company
achieved 22 regulatory approvals worldwide. As of the end of last year, Amgen
had more than thirty-five thousand patients enrolled in clinical studies.
Pipeline expansion continues, as the company announced its intent to put as
many as nine new programs into development in 2004.
"At Amgen we focus on grievous illnesses and hope to ameliorate them by
developing truly innovative therapeutics," said Roger M. Perlmutter, M.D.,
Ph.D., executive vice president of Research and Development for Amgen. "Many
of these potential molecules could create new treatment standards for people
who suffer from debilitating illnesses."
Amgen's R&D organization follows four guiding principles: focus on
grievous illness; be modality independent; understand efficacy in patients
earlier; and ensure seamless integration from basic research through
"To be successful, the commercialization process has to be a deeply
collaborative one from the outset," said George Morrow, executive vice
president of Global Commercial Operations for Amgen. "Together, we ask the
questions: Is there a need in the marketplace? What unique benefits might the
product offer? Can we advance the practice of medicine? Amgen is not
interested in developing 'me-too' therapies, or treating diseases for which a
number of effective treatments already exist."
In discussing the pipeline, Amgen highlighted the commercial potential of
select molecules and programs in clinical development.
Click here for link to the informational chart:
A summary of products/programs discussed, including targeted 2004
milestones, is attached in Table 1.
Enbrel(R) (etanercept) has dramatically changed the way physicians treat
inflammatory diseases. Amgen is committed to building on this success by
developing additional therapeutics in this broad disease category. The
company's research focus encompasses the major pathways involved in
inflammatory diseases, including inhibition of pro-inflammatory cytokines,
intracellular pathways and B-cell activation and differentiation. The company
discussed seven programs in this disease area.
Amgen reported on its marketed inflammation products Enbrel and
Kineret® (anakinra). Last year, Amgen and Wyeth Pharmaceuticals
submitted a supplemental Biologics License Application (sBLA) for the use
of Enbrel in the treatment of moderate to severe plaque psoriasis.
Psoriasis, a disease characterized by chronic inflammation of the skin,
affects nearly five million people in the U.S. Amgen indicated that they
expect to get approval for psoriasis in 2004. Enbrel is already approved
to treat rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic
arthritis, and ankylosing spondylitis.
Kineret, also indicated for the treatment of rheumatoid arthritis, was
shown to relieve pain in a small pilot clinical study in the treatment of
osteoarthritis. Amgen announced that it plans to initiate a Phase 2
clinical study with Kineret in osteoarthritis (OA) in 2004.
AMG 108 is a monoclonal antibody that blocks the action of Interleukin-1
(IL-1), a cytokine that is believed to play a role in the joint
destruction associated with OA. In a Phase 1 clinical study, AMG 108
administered subcutaneously (SC) was well-tolerated, and the clinical
data suggests pharmaceutical properties consistent with infrequent
dosing. Phase 2 clinical studies are expected to begin in 2004.
AMG 714 is a human monoclonal antibody directed against Interleukin-15
(IL-15) that is being developed under an agreement with Genmab S/A to
treat inflammatory and autoimmune diseases. AMG 714 is currently being
evaluated in Phase 2 clinical studies for rheumatoid arthritis. Interim
results suggest that AMG 714 may improve the signs and symptoms of
rheumatoid arthritis. Amgen expects to complete this Phase 2 clinical
evaluation in 2004.
Amgen discussed its p38 antagonist small molecule program. The p38 MAP
kinase regulates a number of intracellular signaling pathways being
targeted by Amgen. Inhibition of p38 kinase reduces expression of a
variety of inflammatory mediators, including Tumor Necrosis Factor (TNF)
and IL-1. Amgen anticipates completing the Phase 1 clinical studies with
a p38 antagonist in 2004.
B-cell activating factor (BAFF) antagonist
Amgen also discussed a B-cell activating factor (BAFF) antagonist program
that reduces the production of abnormally functioning B-cells. This
therapeutic target may have clinical utility in systemic lupus
erythematosus and rheumatoid arthritis. Amgen plans to initiate Phase 1
clinical studies with a lead candidate from the BAFF antagonist program
Metabolic Disease and Osteoporosis
Amgen also reported on its expanding research into metabolic disorders.
Amgen discussed an 11B-HSD1 small molecule program that Amgen has
exclusive rights to develop and commercialize based on an agreement with
Biovitrum AB. Small-molecule 11B-HSD1 enzyme inhibitors are being
developed for the treatment of metabolic diseases, offering a unique
mechanism that could potentially alter the therapy for type 2 diabetes.
Additional clinical studies are planned in 2004.
Another area of focus for Amgen is osteoporosis, which results in
significant economic burden on health care systems.
AMG 162 is Amgen's fully human monoclonal antibody that specifically
targets the receptor activator of nuclear factor kappa B ligand (RANKL),
a key mediator of the body's natural pathway of the resorptive phase of
bone remodeling. Amgen is the innovator of this biologic response
modifier, one which may offer improved therapy for diseases associated
with bone loss, like osteoporosis. Intended to be administered twice-
yearly through SC injections, AMG 162 has the potential to
address key unmet patient and physician needs. Amgen presented interim
data from a Phase 2 clinical study demonstrating the clinical effect of
AMG 162 on bone endpoints. Based on preliminary clinical data, AMG 162
appears to be well-tolerated. Amgen anticipates the initiation of a Phase
3 clinical study with AMG 162 in osteoporosis in 2004.
Amgen is building upon its heritage as a pioneer in science while
leveraging its expertise in protein, antibody and small molecule research.
Amgen's approach to oncology lies in its ability to identify, characterize and
target novel proteins that are involved in cancer biology. These proteins
often endow tumor cells with the activity to circumvent normal growth
regulation. Amgen is focused on understanding these properties, which are
common to many different types of cancer. In addition, Amgen is dedicated to
providing cancer patients with supportive care products, which facilitate the
ability to deliver chemotherapy and/or radiotherapy. The company discussed
nine programs in this therapeutic area.
In addition to its potential use in osteoporosis, AMG 162 is being
studied in metastatic bone disease for the suppression of bone loss in
patients with cancer. Amgen expects to initiate Phase 2 clinical studies
of AMG 162 in metastatic bone disease in 2004.
Palifermin is a recombinant human keratinocyte growth factor (rHuKGF)
that appears to protect the epithelial cells lining the mouth and gut
from damage caused by chemotherapy and/or radiotherapy. It is being
pursued for the treatment of oral mucositis, a painful condition
characterized by severe mouth sores often requiring supplemental
nutritional support. This is one of the most debilitating side effects
of cancer treatment. Approximately four hundred thousand patients in the
U.S. suffer from mucositis during cancer treatment, with no effective
standard therapy available. Amgen confirmed plans to submit marketing
applications in the United States and Europe in 2004 for palifermin in
the bone marrow transplant setting.
Neulasta® and Aranesp®
Amgen discussed the continuing development of supportive care oncology
products Neulasta® (pegfilgrastim), Amgen's once-per-cycle product for
decreasing the incidence of infections associated with many types of
cancer chemotherapy treatments, and Aranesp® (darbepoetin alfa), its
latest product for the treatment of anemia associated with chronic kidney
disease and chemotherapy-induced anemia. Neulasta clinical studies are
focused on first-cycle use in patients with moderate risk for febrile
neutropenia, support of dose-dense chemotherapy, and the development of
methods to identify patients at risk of developing febrile neutropenia
who should benefit from prophylactic use of Neulasta.
Aranesp's continued development includes clinical studies using less
frequent dosing as well as therapeutic trials in patients suffering from
the anemia of cancer.
AMG 114 is a hyperglycosylated analog of Aranesp, which has shown greater
in vivo potency than epoetin alfa or darbepoetin alfa in preclinical
studies and is being developed to treat chemotherapy-induced anemia.
Amgen expects to initiate Phase 1/2 clinical studies with AMG 114 in
Panitumumab (rHuMAb-EGFr) is the first fully human monoclonal antibody
directed against the epidermal growth factor receptor (EGFr). It is
being evaluated as monotherapy and in combination with other agents for
the treatment of various solid tumor cancers in partnership with Abgenix,
Inc. In 2004, Amgen initiated pivotal clinical studies in panitumumab as
a third-line monotherapy in colorectal cancer patients with a convenient
every-other-week dosing regimen.
Amgen discussed the Apo2L/TRAIL molecule that they are developing in
collaboration with Genentech, Inc. Apo2L/TRAIL is a soluble human protein
involved in the regulation of apoptosis, also known as programmed cell
death. Amgen and Genentech anticipate initiation of Phase 1 clinical
studies with Apo2L/TRAIL in the third quarter of 2004.
Amgen introduced its small molecule angiogenesis inhibitor, AMG 706,
which selectively inhibits multiple kinases. Amgen is encouraged by
early clinical data that show signs of tumor regression, along with
promising preliminary data that potentially allow for combination
therapy. Amgen expects to complete a Phase 1 clinical study with AMG 706
Angiopoietin (ANG) Receptor Antagonist
Amgen also discussed its Angiopoietin (ANG) Receptor Antagonist program.
This novel molecule inhibits tumor growth and reduces the viable tumor
fraction in preclinical models. Amgen expects to initiate Phase 1
clinical studies with a lead ANG antagonist candidate from this program
Hematology and Nephrology
Amgen has a proven track record in hematology with its work in
discovering, developing and marketing products such as Epogen® (epoetin
alfa), Neupogen® (filgrastim), Aranesp and Neulasta. Amgen reported on its
further development efforts with Aranesp in the chronic kidney disease patient
population with the planned initiation in 2004 of the Trial to Reduce
Cardiovascular Events with Aranesp Therapy (TREAT).
Amgen presented associative data suggesting that congestive heart failure
(CHF) patients with low hemoglobin levels are at increased risk for death
(all-cause mortality). Amgen discussed plans to complete enrollment in an
Aranesp Phase 2 study in anemic CHF patients in 2004.
Amgen reported on alfimeprase, a modified fibrolase that directly
degrades fibrin when delivered through a catheter at the site of a blood
clot, which is being developed in collaboration with Nuvelo. Alfimeprase
is currently in a Phase 2 clinical study in patients with peripheral
arterial occlusion (PAO). PAO occurs when a clot blocks arterial blood
flow to an extremity. Phase 2 alfimeprase clinical studies in patients
with PAO are expected to be completed in 2004.
AMG 531 is a first-in-class molecule with a novel mechanism of action in
Phase 2 clinical development for the treatment of immune (idiopathic)
thrombocytopenic purpura (ITP), a serious unmet need. ITP is an
autoimmune bleeding disorder characterized by an insufficient number of
platelets; specialized blood cells that help prevent and stop bleeding.
There are approximately seventy thousand adult patients diagnosed in the
U.S. with ITP. Unlike current therapies, AMG 531 stimulates platelet
production. Amgen anticipates completing Phase 2 clinical studies with
AMG 531 in 2004.
Sensipar(TM) (cinacalcet HCl) is a first-in-class oral calcimimetic,
recently approved by the FDA for once-daily administration in patients
with secondary hyperparathyroidism (HPT) on dialysis and for the
treatment of elevated levels of calcium in patients with parathyroid
cancer. Secondary HPT in patients with chronic kidney disease on
dialysis affects approximately three hundred thirty-five thousand
patients in the U.S. and an additional two hundred twenty thousand
patients in Europe. Sensipar is the only available treatment that may
enable patients to simultaneously achieve target levels of PTH, calcium,
phosphorus and calcium-phosphorus product as recommended in the Kidney
Disease Outcomes Quality Initiative (K/DOQI) clinical practice guidelines
recently issued by the National Kidney Foundation. Amgen licensed
Sensipar from NPS Pharmaceuticals Inc. in 1996.
Amgen reported on its neurology program, which is focused on discovering
and developing therapeutics targeting neurodegenerative diseases such as
Parkinson's Disease. For the first time, Amgen revealed research efforts into
novel neuropathic and inflammatory pain therapeutics.
Nerve Growth Factor (NGF) antagonist
Amgen highlighted the company's Nerve Growth Factor (NGF) antagonist
program targeting neuropathic pain, an often long-lasting debilitating
condition associated with diabetic and post-herpetic neuropathy. Painful
diabetic neuropathy is the most common neuropathic condition, affecting
approximately five million diabetics in the U.S. alone. Several
approaches are being explored to target NGF, including a neurotrophic
factor that controls expression of pain mediators in nerve terminals
Amgen anticipates completing the Phase 1 clinical study for the NGF
program in 2004
Vanilloid Receptor 1 (VR1) antagonist
Amgen also discussed a Vanilloid Receptor 1 (VR1) antagonist small
molecule program. VR1 is a receptor found in pain-sensing nerves
Preclinical results demonstrate long-lasting relief of inflammatory pain
Approximately fifty million people in the U.S. suffer from chronic pain
and pain is the number one reason people seek health care treatment
About 40 percent of people with moderate to severe pain are unable to
achieve adequate pain relief. Amgen anticipates initiating Phase 1
clinical studies with a VR1 antagonist in 2004
Glial cell derived neurotrophic factor (GDNF)
Glial cell derived neurotrophic factor (GDNF) is currently in Phase 2
placebo-controlled clinical studies in patients with advanced Parkinson's
Disease. There are over one million patients diagnosed with Parkinson's
Disease in the U.S.; approximately 15 percent are severely disabled. GDNF
is a naturally-occurring protein. Preclinical data suggest that GDNF both
protects and stimulates regeneration of neurons that secrete dopamine
the same neurons that are progressively lost in Parkinson's Disease
Amgen has developed a recombinant protein analogue of naturally occurring
GDNF, a potential first-in-class breakthrough therapy for advanced
An open label clinical study of GDNF with five patients showed sustained
and progressive improvement in motor function and increased neuronal
fluorodopa uptake. Phase 2 clinical studies with GDNF in advanced
Parkinson's Disease patients are expected to be completed in 2004.
Milestones in 2004
Inflammation Enbrel® Approval for
Kineret(R) Initiate Phase 2 -
AMG 108 Initiate Phase 2 -
AMG 714 Complete Phase 2 -
p38 Antagonist Complete Phase 1
BAFF Antagonist Initiate Phase 1
Metabolic and 11B-HSD1 Initiate
Osteoporosis Additional Studies
AMG 162 Initiate Phase 3 -
Oncology AMG 162 Initiate Phase 2 -
Palifermin US/EU Mucositis
Neulasta® Complete Moderate
Aranesp® Initiate Extended
Dosing Study -
AMG 114 Initiate Phase 1/2
Panitumumab Enroll Pivotal
Study - Colorectal
Apo2L/TRAIL Initiate Phase 1
AMG 706 Complete Phase 1
Receptor Antagonist Initiate Phase 1
Hematology and Aranesp® Initiate TREAT
Nephrology Outcomes Study -
Aranesp® Enroll Phase 2 -
Alfimeprase Complete Phase 2 -
AMG 531 Complete Phase 2 -
Neurology NGF Antagonist Complete Phase 1
VR1 Antagonist Initiate Phase 1
GDNF Complete Phase 2 -
The company also indicated that the following long-term guidance provided
at its Business Review Meeting held in February 2003 remains achievable: the
company expected product sales to increase at a compound annual growth rate in
the 30 to 32 percent range during the 2002 through 2005 time period and
expected adjusted earnings per share to grow in the 25 to 27 percent range for
the same period. The company stated that these growth rates assume no
acquisitions or product in-licensing and that its present understanding of
Medicare reimbursement changes remains limited.
Adjusted earnings per share for the period 2002 through 2005 exclude
certain expenses related to the acquisition of Immunex and certain non-
recurring items. These expenses and non-recurring items are reconciled in the
reconciliation table below.
FORWARD LOOKING STATEMENTS
This news release contains forward-looking statements that involve
significant risks and uncertainties, including those discussed below and
others that can be found in Amgen's Form 10-K for the year ended December 31,
2003, and in Amgen's periodic reports on Form 10-Q and Form 8-K. Amgen is
providing this information as of the date of this news release and does not
undertake any obligation to update any forward-looking statements contained in
this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may
differ materially from those we project. Discovery or identification of new
product candidates or development of new indications for existing products
cannot be guaranteed and movement from concept to product is uncertain;
consequently, there can be no guarantee that any particular product candidate
or development of a new indication for an existing product will be successful
and become a commercial product. Further, preclinical results do not
guarantee safe and effective performance of product candidates in humans. The
complexity of the human body cannot be perfectly, or sometimes, even
adequately modeled by computer or cell culture systems or animal models. The
length of time that it takes for us to complete clinical trials and obtain
regulatory approval for product marketing has in the past varied and we expect
similar variability in the future. We develop product candidates internally
and through licensing collaborations, partnerships and joint ventures.
Product candidates that are derived from relationships may be subject to
disputes between the parties or may prove to be not as effective or as safe as
we may have believed at the time of entering into such relationship. Also, we
or others could identify side effects or manufacturing problems with our
products after they are on the market. In addition, sales of our products are
affected by the availability of reimbursement and the reimbursement policies
imposed by third party payors, including governments, private insurance plans
and managed care providers, and may be affected by domestic and international
trends toward managed care and healthcare cost containment as well as possible
U.S. legislation affecting pharmaceutical pricing and reimbursement.
Government regulations and reimbursement policies may affect the development,
usage and pricing of our products. In addition, we compete with other
companies with respect to some of our marketed products as well as for the
discovery and development of new products. We believe that some of our newer
products, product candidates or new indications for existing products, may
face competition when and as they are approved and marketed. Our products may
compete against products that have lower prices, established reimbursement,
superior performance, are easier to administer, or that are otherwise
competitive with our products. In addition, while we routinely obtain
patents for our products and technology, the protection offered by our patents
and patent applications may be challenged, invalidated or circumvented by our
competitors and there can be no guarantee of our ability to obtain or maintain
patent protection for our products or product candidates. We cannot guarantee
that it will be able to produce commercially successful products or maintain
the commercial success of our existing products. Our stock price may be
affected by actual or perceived market opportunity, competitive position, and
success or failure of our products or product candidates. Further, the
discovery of significant problems with a product similar to one of our
products that implicate an entire class of products could have a material
adverse effect on sales of the affected products and on our business and
results of operations.
The scientific information discussed in this presentation related to our
product candidates is preliminary and investigative. Such product candidates
are not approved by the U.S. Food and Drug Administration (FDA), and no
conclusions can or should be drawn regarding the safety or effectiveness of
the product candidates. Only the FDA can determine whether the product
candidates are safe and effective for the uses being investigated. Further,
the scientific information discussed in this presentation relating to new
indications for our approved products is preliminary and investigative and is
not part of the labeling approved by the FDA for the products. Healthcare
professionals should refer to and rely upon the FDA-approved labeling for the
products, and not the information discussed in this presentation.
Amgen is a global biotechnology company that discovers, develops,
manufactures and markets important human therapeutics based on advances in
cellular and molecular biology.
Reconciliation of GAAP (loss) earnings per share to "Adjusted" earnings
(In millions, except per share data)
Historical results Implied results
for year ended for year ended
GAAP (loss) earnings per share $(1.21) $2.55 - $2.69
Adjustments to GAAP (loss) earnings
Write-off of acquired in-process
research and development 2.53 (1) --
Amortization of acquired
intangible assets 0.12 (1) 0.16 (1)
Other merger related expenses 0.06 (1) --
Litigation settlement (0.12) --
Amgen Foundation contribution 0.03 --
Termination of collaboration
agreements (0.03) --
"Adjusted" earnings per share $1.38 $2.71 - $2.85
Adjustment for interest expense
on convertible notes $0.01 (2) $--
"Adjusted" earnings per share $1.39 (3) $2.71 - $2.85
(1) Incurred in connection with the Immunex acquisition in July 2002.
(2) Pursuant to the if-converted method of calculating EPS, the
numerator for "Adjusted" EPS in 2002 reflects the avoidance of
interest expense incurred, net of tax, related to the assumed
conversion of the convertible notes. The conversion of such debt
and the avoidance of interest expense is not assumed for calculating
the GAAP EPS because its impact is anti-dilutive due to the GAAP net
loss in 2002.
(3) Due to the GAAP net loss in 2002, shares used in calculating the
GAAP loss per share exclude the impact of stock options and
convertible notes because their impact was anti-dilutive. Shares
used in calculating the "Adjusted" earnings per share for 2002
include the impact of dilutive stock options (27.1 million shares)
and convertible notes (29.3 million shares) under the treasury stock
and "if-converted" methods, respectively.
Summary reconciliation of "Adjusted" EPS CAGR to GAAP EPS CAGR
For the 2002-2005 period
"Adjusted" EPS CAGR (Guidance) 25% - 27%
GAAP EPS CAGR N/A (1)
(1) Due to the GAAP loss per share of ($1.21) in 2002, a GAAP EPS CAGR
for the 2002-2005 period cannot be calculated.
Amgen, Thousand Oaks
Sabrina Johnson, (805) 447-4587 (media)
Cary Rosansky, (805) 447-1060 (investors)